SCHEMBL12460586

SCHEMBL12460586

Cc1cc(C(C)C)nc(C(C)(C)C)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.53
NOS1 P29475 1/20 0.53
NOS2 P35228 1/20 0.53
HMGCR P04035 3/20 0.44
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CRHBP P24387 1/20 0.38
CYP2C19 P33261 1/20 0.38
CRHR2 Q13324 1/20 0.38
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.32
ALDH1A1 P00352 1/20 0.31
CA2 P00918 1/20 0.31
POLB P06746 1/20 0.31
TYR P14679 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2A6 P11509 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27270598 0.84 NOS3 (0.50) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL21212137 0.82 CYP3A4 (0.58) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL6662711 0.79 NOS2 (0.70) NOS3NOS1NOS2TSHRCYP3A4
SCHEMBL37832 0.79 ALDH1A1 (0.40) NOS3NOS1NOS2HMGCRTSHR
Bromide SCHEMBL10759230 0.77 HSD17B10 (0.39) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL28111108 0.76 HSD17B10 (0.35) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL17281791 0.75 CYP3A4 (0.42) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL16259689 0.75 HMGCR (0.42) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL13019465 0.73 HRH4 (0.44) NOS3NOS1NOS2HMGCRTSHR
SCHEMBL25140647 0.73 HMGCR (0.40) NOS3NOS1NOS2HMGCRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2013-08-01 US disclosed
EP-2343286-A1 Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase Methylgene, Inc. (CA) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196987-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS FLT4, VEGFA, FLT1 NOS3 254/4885NOS1 756/4885NOS2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.